{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:58:00Z","timestamp":1780372680431,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.semarthrit.2024.152389","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T19:09:23Z","timestamp":1706123363000},"page":"152389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The management of cardiovascular risk in psoriatic disease: A bridge over troubled water"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-5640","authenticated-orcid":false,"given":"Alessia","family":"Alunno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobh\u00e1n","family":"Donohoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.semarthrit.2024.152389_bib0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152389_bib0002","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/jdv.13170","article-title":"Association of psoriasis and\/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology\/Rheumatology outpatient clinics","volume":"29","author":"Carubbi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primer"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"34","key":"10.1016\/j.semarthrit.2024.152389_bib0005","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0006","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152389_bib0007","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152389_bib0008","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard-2023-224148","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"10.1016\/j.semarthrit.2024.152389_bib0009","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/heartjnl-2019-316193","article-title":"Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study","volume":"106","author":"Nikiphorou","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X21998279","article-title":"Psoriatic arthritis and the association with cardiometabolic disease: a narrative review","volume":"13","author":"Karmacharya","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0011","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/art.42694","article-title":"Derivation and internal validation of a disease-specific cardiovascular risk prediction model for patients with psoriatic arthritis and psoriasis","volume":"76","author":"Colaco","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152389_bib0012","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamasurg.2016.4610","article-title":"Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery","volume":"152","author":"Egeberg","year":"2017","journal-title":"JAMA Surg"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0013","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/oby.21955","article-title":"Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study","volume":"25","author":"Maglio","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152389_bib0014","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/acr.22536","article-title":"Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study","volume":"67","author":"Ernste","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152389_bib0016","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152389_bib0017","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s10067-019-04528-y","article-title":"Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study","volume":"38","author":"Kibari","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2019.07.103","article-title":"Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis","volume":"82","author":"Wu","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152389_bib0019","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1093\/rheumatology\/keaa720","article-title":"Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk","volume":"60","author":"Toussirot","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152389_bib0020","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/rheumatology\/keaa604","article-title":"Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity\u2014a cross-sectional study","volume":"60","author":"Ferguson","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152389_bib0021","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/ard.2006.060319","article-title":"Redefining overweight and obesity in rheumatoid arthritis patients","volume":"66","author":"Stavropoulos-Kalinoglou","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/acr.20363","article-title":"Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res Hoboken"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152389_bib0023","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0024","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5114\/aoms.2018.74021","article-title":"Serum lipid metabolism in psoriasis and psoriatic arthritis - an update","volume":"15","author":"Pietrzak","year":"2019","journal-title":"Arch Med Sci AMS"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152389_bib0025","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1111\/ijd.12921","article-title":"Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis","volume":"54","author":"Wu","year":"2015","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0026","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1007\/s10067-020-05132-1","article-title":"Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing","volume":"39","author":"Su","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152389_bib0027","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152389_bib0028","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0029","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/rheumatology\/ket343","article-title":"Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study","volume":"53","author":"Dubreuil","year":"2014","journal-title":"Rheumatol Oxf Engl"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152389_bib0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.160861","article-title":"The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study","volume":"44","author":"Eder","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/580404","article-title":"Psoriatic arthritis and diabetes: a population-based cross-sectional study","volume":"2013","author":"Dreiher","year":"2013","journal-title":"Dermatol Res Pract"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152389_bib0032","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152389_bib0033","doi-asserted-by":"crossref","first-page":"e19303","DOI":"10.1097\/MD.0000000000019303","article-title":"A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates","volume":"99","author":"Duan","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"10.1016\/j.semarthrit.2024.152389_bib0034","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0035","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152389_bib0037","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0038","article-title":"Cardiovascular risk in patients with psoriatic arthritis","volume":"2012","author":"Zhu","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.735150","article-title":"Psoriatic arthritis and metabolic syndrome: is there a role for disease modifying anti-rheumatic drugs?","volume":"8","author":"Atzeni","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13075-015-0570-0","article-title":"Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study","volume":"17","author":"Shen","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152389_bib0041","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/art.40389","article-title":"Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity","volume":"70","author":"Szentpetery","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0042","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152389_bib0044","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","article-title":"Cardiovascular effects and safety of (non-aspirin) NSAIDs","volume":"17","author":"Schjerning","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0045","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152389_bib0046","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/B:EJEP.0000020447.59150.f9","article-title":"Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients","volume":"19","author":"Mallbris","year":"2004","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152389_bib0047","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15021","article-title":"Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study","volume":"176","author":"Springate","year":"2017","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152389_bib0048","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/art.22800","article-title":"Improved survival in psoriatic arthritis with calendar time","volume":"56","author":"Ali","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152389_bib0049","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jid.2017.01.036","article-title":"All-cause and cause-specific mortality in patients with psoriasis in Taiwan: a nationwide population-based study","volume":"137","author":"Lee","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152389_bib0050","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.30277","article-title":"Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0051","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3899\/jrheum.160070","article-title":"Disease activity and increased risk of cardiovascular death among patients with psoriatic arthritis","volume":"43","author":"Juneblad","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0052","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2012-202424","article-title":"Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study","volume":"73","author":"Ogdie","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152389_bib0053","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/kew502","article-title":"Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Ogdie","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0054","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3899\/jrheum.080691","article-title":"Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study","volume":"36","author":"Wilson","year":"2009","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152389_bib0055","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaad.2020.10.031","article-title":"Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada","volume":"84","author":"Colaco","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0056","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.23548","article-title":"Causes of death in rheumatoid arthritis: how do they compare to the general population?","volume":"70","author":"Widdifield","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0057","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"10354","key":"10.1016\/j.semarthrit.2024.152389_bib0058","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152389_bib0059","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review","volume":"61","author":"Vincken","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0060","unstructured":"2023 EULAR PsA Recommendations Update. Available from: www.medscape.com\/viewarticle\/993015. [Accessed 2 July 2023]."},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0062","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fphar.2020.00481","article-title":"Impact of TNF-\u03b1 inhibitors on body weight and BMI: a systematic review and meta-analysis","volume":"11","author":"Patsalos","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000763","article-title":"Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials","volume":"5","author":"Champs","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0064","article-title":"Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis","volume":"8","author":"Baoqi","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0065","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152389_bib0066","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"suppl 9","key":"10.1016\/j.semarthrit.2024.152389_bib0067","article-title":"Biological therapies for psoriasis and psoriatic arthritis-effects on future risk development of major adverse cardiovascular events (MACE)","volume":"75","author":"Dotan","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0068","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.biopha.2018.07.110","article-title":"The pleiotropic role of interleukin-17 in atherosclerosis","volume":"106","author":"Allam","year":"2018","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0069","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/ATVBAHA.114.303567","article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles","volume":"35","author":"Taleb","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152389_bib0070","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF Inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0071","article-title":"Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152389_bib0072","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody ustekinumab","volume":"156","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152389_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102902","article-title":"JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis","volume":"20","author":"Campanaro","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152389_bib0074","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152389_bib0075","unstructured":"European Medicines Agency. Janus kinase inhibitors (JAKi)\u2014referral; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki. [Accessed 14 December 2023]."},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152389_bib0076","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","article-title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"6","author":"Sarabia","year":"2022","journal-title":"BMC Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152389_bib0077","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamadermatol.2021.4467","article-title":"Analysis of specialist and patient perspectives on strategies to improve cardiovascular disease prevention among persons with psoriatic disease","volume":"158","author":"Barbieri","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152389_bib0078","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152389_bib0079","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152389_bib0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2014-206617","article-title":"Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation?","volume":"74","author":"Kristensen","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152389_bib0081","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:14:25Z","timestamp":1758734065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":81,"alternative-id":["S0049017224000301"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152389","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of cardiovascular risk in psoriatic disease: A bridge over troubled water","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152389"}}